, Tracking Stock Market Picks
Enter Symbol:
Allos Therapeutics, Inc. (ALTH) [hlAlert]

Mkt Outperform
down 66.48 %

Allos Therapeutics, Inc. (ALTH) rated Mkt Outperform by Rodman & Renshaw

Posted on: Wednesday,  Dec 10, 2008  8:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Allos Therapeutics, Inc. (NASDAQ: ALTH) on 12/10/2008, when the stock price was $5.49.
Since then, Allos Therapeutics, Inc. has lost 66.48% as of 09/05/2012's recent price of $1.84.
If you would have followed this Rodman & Renshaw's recommendation on ALTH, you would have lost 66.48% of your investment in 1365 days.

Allos Therapeutics is a pharmaceutical company focused on developing andcommercializing innovative small molecule drugs, initially for improving cancer treatments. The company's lead product candidate is RSR13. RSR13 is a synthetic small molecule that increases the release of oxygen from hemoglobin, the oxygen-carrying protein contained within red blood cells.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/10/2008 8:25 AM Buy
as of 12/24/2008
1 Week down  -1.37 %
1 Month down  -6.04 %
3 Months   
1 YTD down  -6.04 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy